In a report released today, Charles Zhu from LifeSci Capital maintained a Hold rating on Repare Therapeutics (RPTX – Research Report). The ...

Investment analysts at Lifesci Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Perspective ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC ...

Discover Celcuity's Q4 2024 insights: gedatolisib's promising trials for breast cancer, $2B market potential, and key 2025 milestones.

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research ...

Insiders have been showing their love for these four biotech stocks, and one tech stock, lately with huge share purchases.

Q4 2024 Earnings Call Transcript March 28, 2025 Humacyte, Inc. beats earnings expectations. Reported EPS is $-0.16, ...

Brainomix, an Oxford-born company pioneering AI-powered imaging tools in stroke and lung fibrosis, has clinched an $18 ...

LifeSci Capital has initiated coverage with an Outperform rating. Citigroup recently maintained its Buy rating, while H.C. Wainwright reiterated a Neutral rating. German clinical-stage ...

Operator: Thank you. Your next question comes from the line of Rami Katkhuda from LifeSci Capital. Please go ahead. Rami Katkhuda: Hey guys, thanks for taking my questions. I guess first ...

LifeSci Capital is acting as the lead manager for the proposed offering. In another sign that the biotech IPO market is picking up, cell therapy specialist Kyverna has filed to raise roughly $211 ...